Ibogaine vs. Ketamine Therapy
Comparing two psychedelic-adjacent treatments for depression, PTSD, and treatment-resistant conditions.
Ibogaine
- • Single treatment session
- • Multi-receptor mechanism (serotonin, dopamine, opioid, NMDA, GDNF)
- • Effects sustained weeks-months via noribogaine
- • Addresses addiction, PTSD, depression simultaneously
- • 12-24 hour experience with visionary component
- • Requires travel to Mexico
- • Not FDA-approved
- • Cardiac monitoring required
Ketamine / Esketamine Therapy
- • Multiple sessions required (6 initial, then maintenance)
- • Primarily NMDA receptor antagonist
- • Effects last days to weeks per session
- • Primarily used for depression (some PTSD research)
- • 40-60 minute infusion sessions
- • Available in the US at ketamine clinics
- • FDA-approved (esketamine/Spravato for depression)
- • Generally well-tolerated
The Bottom Line
Ketamine therapy is more accessible (available in the US), has FDA approval for depression (as esketamine/Spravato), and has a well-established safety profile. However, it requires repeated sessions and ongoing maintenance. Ibogaine's advantage is its single-treatment format, multi-mechanism action, and sustained effects through noribogaine. For treatment-resistant depression specifically, both show promise — and they are not mutually exclusive. Some patients have benefited from both at different points in their treatment journey.
The Ibogaine Briefing
Stay informed — get the latest ibogaine research, news, and stories delivered to your inbox.
We respect your privacy. Unsubscribe anytime.
Medical Disclaimer: The information on this page is for educational purposes only and is not intended as medical advice. Ibogaine treatment carries serious risks including cardiac complications. Always consult a qualified healthcare provider before pursuing any treatment.